155 related articles for article (PubMed ID: 29321484)
1. Loss of tolerance to gut immunity protein, glycoprotein 2 (GP2) is associated with progressive disease course in primary sclerosing cholangitis.
Tornai T; Tornai D; Sipeki N; Tornai I; Alsulaimani R; Fechner K; Roggenbuck D; Norman GL; Veres G; Par G; Par A; Szalay F; Lakatos PL; Antal-Szalmas P; Papp M
Sci Rep; 2018 Jan; 8(1):399. PubMed ID: 29321484
[TBL] [Abstract][Full Text] [Related]
2. Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis.
Jendrek ST; Gotthardt D; Nitzsche T; Widmann L; Korf T; Michaels MA; Weiss KH; Liaskou E; Vesterhus M; Karlsen TH; Mindorf S; Schemmer P; Bär F; Teegen B; Schröder T; Ehlers M; Hammers CM; Komorowski L; Lehnert H; Fellermann K; Derer S; Hov JR; Sina C
Gut; 2017 Jan; 66(1):137-144. PubMed ID: 27406039
[TBL] [Abstract][Full Text] [Related]
3. Rediscovery of the Anti-Pancreatic Antibodies and Evaluation of their Prognostic Value in a Prospective Clinical Cohort of Crohn's Patients: The Importance of Specific Target Antigens [GP2 and CUZD1].
Papp M; Sipeki N; Tornai T; Altorjay I; Norman GL; Shums Z; Roggenbuck D; Fechner K; Stöcker W; Antal-Szalmas P; Veres G; Lakatos PL
J Crohns Colitis; 2015 Aug; 9(8):659-68. PubMed ID: 25968583
[TBL] [Abstract][Full Text] [Related]
4. Mucosal Autoimmunity to Cell-Bound GP2 Isoforms Is a Sensitive Marker in PSC and Associated With the Clinical Phenotype.
Sowa M; Kolenda R; Baumgart DC; Pratschke J; Papp M; Tornai T; Suchanski J; Bogdanos DP; Mytilinaiou MG; Hammermann J; Laass MW; Conrad K; Schramm C; Franke A; Roggenbuck D; Schierack P
Front Immunol; 2018; 9():1959. PubMed ID: 30233574
[No Abstract] [Full Text] [Related]
5. Gut barrier failure biomarkers are associated with poor disease outcome in patients with primary sclerosing cholangitis.
Tornai T; Palyu E; Vitalis Z; Tornai I; Tornai D; Antal-Szalmas P; Norman GL; Shums Z; Veres G; Dezsofi A; Par G; Par A; Orosz P; Szalay F; Lakatos PL; Papp M
World J Gastroenterol; 2017 Aug; 23(29):5412-5421. PubMed ID: 28839442
[TBL] [Abstract][Full Text] [Related]
6. Antibodies against glycoprotein 2 are novel markers of intestinal inflammation in patients with an ileal pouch.
Werner L; Sturm A; Roggenbuck D; Yahav L; Zion T; Meirowithz E; Ofer A; Guzner-Gur H; Tulchinsky H; Dotan I
J Crohns Colitis; 2013 Dec; 7(11):e522-32. PubMed ID: 23639628
[TBL] [Abstract][Full Text] [Related]
7. Evidence of Crohn's disease-related anti-glycoprotein 2 antibodies in patients with celiac disease.
Roggenbuck D; Vermeire S; Hoffman I; Reinhold D; Schierack P; Goihl A; von Arnim U; De Hertogh G; Polymeros D; Bogdanos DP; Bossuyt X
Clin Chem Lab Med; 2015 Aug; 53(9):1349-57. PubMed ID: 25411995
[TBL] [Abstract][Full Text] [Related]
8. Identification of GP2, the major zymogen granule membrane glycoprotein, as the autoantigen of pancreatic antibodies in Crohn's disease.
Roggenbuck D; Hausdorf G; Martinez-Gamboa L; Reinhold D; Büttner T; Jungblut PR; Porstmann T; Laass MW; Henker J; Büning C; Feist E; Conrad K
Gut; 2009 Dec; 58(12):1620-8. PubMed ID: 19549613
[TBL] [Abstract][Full Text] [Related]
9. Anti-glycoprotein 2 (anti-GP2) IgA and anti-neutrophil cytoplasmic antibodies to serine proteinase 3 (PR3-ANCA): antibodies to predict severe disease, poor survival and cholangiocarcinoma in primary sclerosing cholangitis.
Wunsch E; Norman GL; Milkiewicz M; Krawczyk M; Bentow C; Shums Z; Mahler M; Lopens S; Reinhold D; Franke A; Schramm C; Roggenbuck D; Milkiewicz P
Aliment Pharmacol Ther; 2021 Jan; 53(2):302-313. PubMed ID: 33159471
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn's disease.
Bogdanos DP; Roggenbuck D; Reinhold D; Wex T; Pavlidis P; von Arnim U; Malfertheiner P; Forbes A; Conrad K; Laass MW
BMC Gastroenterol; 2012 Aug; 12():102. PubMed ID: 22866900
[TBL] [Abstract][Full Text] [Related]
11. Significance of serological markers in the disease course of ulcerative colitis in a prospective clinical cohort of patients.
Kovacs G; Sipeki N; Suga B; Tornai T; Fechner K; Norman GL; Shums Z; Antal-Szalmas P; Papp M
PLoS One; 2018; 13(3):e0194166. PubMed ID: 29590158
[TBL] [Abstract][Full Text] [Related]
12. Autoantibodies to GP2, the major zymogen granule membrane glycoprotein, are new markers in Crohn's disease.
Roggenbuck D; Reinhold D; Wex T; Goihl A; von Arnim U; Malfertheiner P; Büttner T; Porstmann T; Porstmann S; Liedvogel B; Bogdanos DP; Laass MW; Conrad K
Clin Chim Acta; 2011 Apr; 412(9-10):718-24. PubMed ID: 21195704
[TBL] [Abstract][Full Text] [Related]
13. Autoantibodies Against Glycoprotein 2 Isoforms in Pediatric Patients with Inflammatory Bowel Disease.
Röber N; Noß L; Goihl A; Reinhold D; Jahn J; de Laffolie J; Johannes W; Flemming GM; Roggenbuck D; Conrad K; Laass MW
Inflamm Bowel Dis; 2017 Sep; 23(9):1624-1636. PubMed ID: 28691939
[TBL] [Abstract][Full Text] [Related]
14. Glycoprotein 2 antibodies in Crohn's disease.
Roggenbuck D; Reinhold D; Werner L; Schierack P; Bogdanos DP; Conrad K
Adv Clin Chem; 2013; 60():187-208. PubMed ID: 23724745
[TBL] [Abstract][Full Text] [Related]
15. Primary sclerosing cholangitis is associated with autoreactive IgA antibodies against biliary epithelial cells.
Berglin L; Björkström NK; Bergquist A
Scand J Gastroenterol; 2013 Jun; 48(6):719-28. PubMed ID: 23713804
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic Autoantibodies Against CUZD1 and GP2 Are Associated with Distinct Clinical Phenotypes of Crohn's Disease.
Michaels MA; Jendrek ST; Korf T; Nitzsche T; Teegen B; Komorowski L; Derer S; Schröder T; Baer F; Lehnert H; Büning J; Fellerman K; Sina C
Inflamm Bowel Dis; 2015 Dec; 21(12):2864-72. PubMed ID: 26273818
[TBL] [Abstract][Full Text] [Related]
17. Anti-Outer membrane protein C and anti-glycoprotein 2 antibodies in inflammatory bowel disease and their association with complicated forms of Crohn's disease.
Kohoutova D; Drahosova M; Moravkova P; Rejchrt S; Bures J
BMC Gastroenterol; 2014 Dec; 14():190. PubMed ID: 25551469
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic Potential of Zymogen Granule Glycoprotein 2 Antibodies as Serologic Biomarkers in Chinese Patients With Crohn Disease.
Zhang S; Wu Z; Luo J; Ding X; Hu C; Li P; Deng C; Zhang F; Qian J; Li Y
Medicine (Baltimore); 2015 Oct; 94(42):e1654. PubMed ID: 26496271
[TBL] [Abstract][Full Text] [Related]
19. Serological biomarkers for management of primary sclerosing cholangitis.
Tornai D; Ven PL; Lakatos PL; Papp M
World J Gastroenterol; 2022 Jun; 28(21):2291-2301. PubMed ID: 35800183
[TBL] [Abstract][Full Text] [Related]
20. Antibodies Against Glycoprotein 2 Are Specific Biomarkers for Pediatric Crohn's Disease.
Shpoliansky M; Roggenbuck D; Pinsker M; Salamon N; Weiss B; Shouval DS; Werner L
Dig Dis Sci; 2021 Aug; 66(8):2619-2626. PubMed ID: 32886311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
